Breaks Categories: News

TuesdayFeb 11, 2025 3:30 pm

BioMedNewsBreaks — Titan Partners Group Launches Equity Research Platform Led by Dr. Boris Peaker

Titan Partners, a division of American Capital Partners, today announced the launch of its Equity Research Division with the appointment of Boris Peaker, Ph.D., CFA, as managing director and senior equity research analyst. Dr. Peaker brings 17 years of experience in healthcare equity research and will lead the firm's research initiatives in the healthcare sector, focusing on biotechnology. “The launch of our research platform, spearheaded by Dr. Peaker, marks an important milestone in Titan’s growth,” said Jason Sands, co-founder and partner at Titan. “Our mission has always been to build a business around fundamentally strong and scientifically compelling stories. Dr.…

Continue Reading

MondayFeb 10, 2025 2:05 pm

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Subsidiary Global Telesat Communications Expands Partnership With EVERYWHERE Communications

NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd. (GTC), has partnered with EVERYWHERE Communications, Inc. to enhance mission-critical communications for enterprise, government, and humanitarian organizations across Europe. As EVERYWHERE’s preferred connectivity solutions provider in the UK and EU, GTC will help expand real-time global communications, situational awareness, and workforce safety solutions. The partnership will introduce advanced satellite hotspots, IoT connectivity, and integrated communications platforms to support operations in remote environments. To view the full press release, visit: https://ibn.fm/9Rzgm About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and…

Continue Reading

MondayFeb 10, 2025 1:39 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the BIO CEO & Investor Conference in New York on Feb. 10-11, 2025. CEO John Climaco is scheduled to present on Feb. 10 at 1:15 p.m. ET in the Royale Room. Management will also be available for one-on-one meetings, with scheduling available through the BIO CEO attendee portal. To view the full press release, visit https://ibn.fm/alIXv About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary…

Continue Reading

MondayFeb 10, 2025 12:57 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Engages Enterprise Canada, Empire Market Ventures for PR, Investor Awareness

Quantum BioPharma (NASDAQ: QNTM) has retained Enterprise Canada Inc. and Empire Market Ventures, LLC to lead its public relations and investor awareness efforts. Enterprise, engaged indefinitely, will develop the company’s media strategy, while Empire, engaged for three months starting Feb. 7, 2025, will focus on investor marketing and outreach. The company highlighted progress on its key products, including unbuzzd™, a rapid alcohol detoxification beverage set for Q1 2025 availability, rekvry™, an alcohol misuse treatment, and LUCID-21-302, a potential multiple sclerosis treatment moving toward Phase 2 trials. To view the full press release, visit https://ibn.fm/BxkjT About Quantum BioPharma Ltd. Quantum BioPharma is a…

Continue Reading

FridayFeb 07, 2025 10:35 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference

Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced that CEO Maria Maccecchini, Ph.D., will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on Feb. 11, 2025, from 12:40 to 1:10 p.m. ET. The virtual presentation will cover the company’s progress on its pivotal Phase 3 trial for early Alzheimer’s disease and strategic plans for a New Drug Application for buntanetap. The conference gathers industry leaders and investors to discuss key innovations and market trends in healthcare and life sciences. To view the full press release, visit https://ibn.fm/VFXm1 About Annovis Bio Inc.…

Continue Reading

ThursdayFeb 06, 2025 1:40 pm

BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Announces Board Appointment of UFC Senior Executive Reed Harris

BioAdaptives (OTC: BDPT), a leading biotechnology company focused on innovative health and wellness solutions, has announced the appointment of Reed Harris to its board of advisors. Harris, the senior VP of athlete development and marketing at the Ultimate Fighting Championship (“UFC”) in Las Vegas, brings decades of experience in leadership, athlete development and business management, as well as a proven commitment to driving innovation and excellence. “Reed’s exceptional leadership, business acumen and dedication to athlete development and community service align perfectly with our mission to deliver innovative health and wellness solutions,” said Jim Keener, CEO of BioAdaptives. “His deep experience…

Continue Reading

ThursdayFeb 06, 2025 9:45 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial

Annovis Bio (NYSE: ANVS) announced that the first two patients have been enrolled in its pivotal Phase 3 trial evaluating buntanetap for early Alzheimer’s disease. The randomized, placebo-controlled study will assess the drug’s symptomatic and potential disease-modifying effects over 18 months. Following positive Phase 2/3 results, the trial received FDA approval and aims to enroll over 750 participants across approximately 100 U.S. sites. The company recently secured $21 million in funding to support the initial six-month phase, with the remaining study expected to be funded through warrant exercises. To view the full press release, visit https://ibn.fm/MxaD5 About Annovis Bio Inc.…

Continue Reading

WednesdayFeb 05, 2025 11:56 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development

Annovis Bio (NYSE: ANVS), a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public offering, raising $21 million in gross proceeds. The offering included 5.25 million shares of common stock and warrants at a combined price of $4.00 per share, with warrants exercisable at $5.00 per share for five years. The company plans to use the funds primarily for the continued Phase 3 development of its lead Alzheimer’s drug, Buntanetap, as well as for working capital and corporate purposes. ThinkEquity acted as the sole book-running manager. To view the full press release, visit https://ibn.fm/rOYgn…

Continue Reading

TuesdayFeb 04, 2025 3:07 pm

BioMedNewsBreaks — BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT) Announces Pricing of $3.05M Public Offering

BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announced the pricing of a best-efforts public offering of 762,500 common shares, each at a public offering price of $4.00. The company expects $3.05 million in total gross proceeds from the offering, of which it intends to use the net for working capital, general corporate purposes, and the advancement of business objectives. Subject to the satisfaction of customary conditions, the offering is expected to close on Feb. 5, 2025. ThinkEquity is acting as the sole placement agent for the offering. To…

Continue Reading

TuesdayFeb 04, 2025 10:46 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Positive Clinical Trial Results for unbuzzd™

Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of a clinical trial demonstrating that its dietary supplement, unbuzzd™, significantly accelerates alcohol metabolism and reduces symptoms of intoxication and hangovers. The double-blind, placebo-controlled study showed that unbuzzd™ lowered blood alcohol concentration by over 40% faster within 30 minutes compared to placebo, while improving alertness and stabilizing heart rate and blood pressure. Participants also reported reduced mental fatigue and hangover symptoms without adverse side effects. Quantum BioPharma CEO Zeeshan Saeed highlighted unbuzzd™ as a breakthrough in promoting safe and responsible alcohol consumption. To view the full press release, visit https://ibn.fm/jKWGf About Quantum…

Continue Reading